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Abstract: Lennox–Gastaut syndrome (LGS) is a devastating childhood epilepsy syndrome 
characterized by the occurrence of multiple types of seizures and cognitive decline. Most chil-
dren suffer from frequent seizures that are refractory to current medical management. Recent 
clinical trials have suggested that addition of clobazam may improve the clinical outcome for 
some LGS patients. Although clobazam has been available for over five decades, it has only 
recently been approved by the US Food and Drug Administration for this indication. As a 
1,5-benzodiazepine, clobazam is structurally related to the widely used 1,4-benzodiazepines, 
which include diazepam. Clobazam has been shown to modulate GABAergic neurotransmission 
by positive allosteric modulation of GABAA receptors, and to increase expression of transport-
ers for both GABA and glutamate. The active metabolite n-desmethylclobazam (norclobazam) 
also modulates GABAA receptors, and the relative importance of these two compounds in the 
clinical effectiveness of clobazam remains an open question. Clinical trials involving clobazam 
as an addon therapy in a variety of pediatric epilepsy populations have found a significant 
improvement in seizure control. In patients with LGS, clobazam may have greatest efficacy 
for drop seizures. Longstanding clinical experience suggests that clobazam is a safe and well 
tolerated antiepileptic drug with infrequent and mild adverse effects. These results suggest that 
adjunctive treatment with clobazam may be a reasonable option for LGS patients, particularly 
those who are treatment-resistant.
Keywords: benzodiazepine, epilepsy, gamma aminobutyric acid, pediatric, pharmacoresistance
Lennox–Gastaut syndrome
Lennox–Gastaut syndrome (LGS) is a catastrophic epileptic encephalopathy with a 
poor prognosis and limited treatment options. Although rare, LGS constitutes 3%–10% 
of childhood epilepsies, due to its intractable nature.1–5 Generally, LGS onset occurs 
before 8 years of age, with a peak at 3–5 years,5–7 and is more common in males.1,6,8 
LGS is identified by its characteristic triad of symptoms, including multiple generalized 
seizure types, a slow spike and wave (#2.5) pattern in the awake electroencephalogram, 
and cognitive decline. The types of seizures most commonly associated with LGS are 
tonic, atypical absence, myoclonic, and atonic seizures,5,6 but many LGS patients also 
experience generalized tonic-clonic and focal seizures.2,4,6,9,10 In addition to the slow 
spike and wave pattern, bursts of paroxysmal fast activity during sleep are also clas-
sically present on the electroencephalogram and may be associated with subtle tonic 
seizures.1,5,6 Up to 90% of patients with LGS have mental retardation and experience 
cognitive deterioration,2,3 and many children also develop behavioral and psychological 
problems, including aggression, hyperactivity, and characteristics of autism.3,5,11
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LGS often results from an underlying neurological injury 
or disorder, such as hypoxic-ischemic encephalopathy,   cerebral 
palsy, tuberous sclerosis complex, or cortical   dysplasia, but 
approximately 30% of LGS cases are   cryptogenic, having 
no clear cause.1,5–7 Diagnosis is difficult and may take years 
because in addition to the various etiologies of LGS, the 
syndrome lacks a uniform clinical presentation,6 and often 
patients do not have all of the diagnostic elements at the 
onset of epilepsy.5 LGS is resistant to treatment and often, 
in part due to the multiple seizure types, a combination of 
antiepileptic drugs is required.3,6–8,12 LGS is considered an 
epileptic encephalopathy, in which the degree of cognitive 
deterioration present is thought to be related to seizure 
frequency and burden of epileptic discharges.4,5,11
Current treatment options
A broad spectrum antiepileptic drug or combination of anti-
epileptic drugs is frequently necessary to treat the multiple 
seizure types associated with LGS.3,6–8,12 Valproate is often 
used as a first-line treatment for LGS by many physicians 
because it is effective for both generalized and focal seizures 
and is not known to worsen any seizure types associated with 
LGS.13,14 However, valproate is rarely effective as mono-
therapy3 and has not been approved by the US Food and 
Drug Administration for this purpose.3,6,12,15 Adverse events 
related to valproate use can be serious, including hepatic 
toxicity and pancreatitis, and there are many potential drug 
interactions.16
Felbamate, lamotrigine, topiramate, and rufinamide 
are all approved by the Food and Drug Administration as 
adjunctive treatments for LGS. Each of these antiepileptic 
drugs has been tested in randomized, double-blind, placebo-
controlled clinical trials demonstrating their efficacy for 
seizures associated with LGS.3,7,12 There have been no studies 
comparing approved treatment options for LGS patients,15 
and comparing results from different trials is complicated 
by variations in study populations, concurrent use of other 
antiepileptic drugs, and differences in the types of reported 
data.3,7 A Cochrane database review of treatment options 
for LGS included seven randomized, controlled studies that 
evaluated rufinamide, lamotrigine, cinromide, felbamate, 
thyrotropin-releasing hormone, and topiramate in children 
and adults with LGS.7 In each of these studies, the drug being 
evaluated was compared with placebo, with the exception 
of a study evaluating thyrotropin-releasing hormone, which 
compared low-dose and high-dose efficacy. In their review, 
Hancock and Cross7 concluded that an optimum treatment 
option could not be identified from these studies, but that 
lamotrigine, rufinamide, topiramate, and felbamate may be 
useful as adjunctive therapies.
Felbamate was the first antiepileptic drug approved for 
use as addon therapy for LGS.3 Since its approval in 1993, 
felbamate has been associated with aplastic anemia and 
hepatic failure, and due to these severe adverse events, its 
use has been limited to patients who have not responded to 
other antiepileptic drugs.17–19 Lamotrigine, approved as an 
adjunctive treatment for LGS in 1998, is a broad spectrum 
antiepileptic drug that is effective against multiple seizure 
types.20–22 The most common side effect of lamotrigine is 
a mild skin rash,21,23,24 but Stevens–Johnson syndrome and 
toxic epidermal necrolysis have occurred in rare cases.22,23 
Drug interactions with lamotrigine are common, complicat-
ing its use in combination therapy.25 Topiramate, approved 
for use in LGS in 2001, lacks the risk of life-threatening 
adverse events, like those associated with lamotrigine 
and felbamate,3 but has been associated with cognitive 
impairment,26–28 although this can often be minimized by 
slow titration.3,10,15 Rufinamide, approved in 2011, may be 
particularly effective for drop seizures (due to either tonic or 
atonic events) in children with LGS.29 Rufinamide has been 
associated with somnolence and vomiting,29 which can be 
mitigated by slowed titration.30
If pharmacological treatment fails, other options include 
the ketogenic diet, vagus nerve stimulation, corpus callo-
sotomy, and resective surgery.3,6,12 The ketogenic diet, ie, a 
high-fat, low-protein, and low-carbohydrate diet, has been 
shown to decrease drop seizure frequency in patients who 
do not respond to antiepileptic drugs, including patients with 
LGS.31–34 In studies of the ketogenic diet in the treatment 
of children with refractory epilepsy including LGS, the 
diet provided complete seizure control for more than 50% 
of patients.34 Common side effects include gastrointestinal 
symptoms, such as nausea, vomiting, and constipation, 
which may be improved by decreasing the nonlipid to lipid 
ratio. Compliance with the diet may also be difficult to main-
tain in patients with cognitive and behavioral problems.15 
Although vagus nerve stimulation is not as effective in 
patients with LGS as it is in patients with partial epilepsy,35 
it has been demonstrated to decrease seizure frequency 
with minimal adverse effects.35–37 Corpus collosotomy is 
used to decrease the spread of epileptic discharges between 
hemispheres and can be helpful for patients with intractable 
drop attacks.38 There may be a seizure focus in symptomatic 
cases of LGS such as those caused by tuberous sclerosis or 
cortical dysplasia, in which case resective surgery may be 
effective.12,39
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Each of the approved antiepileptic drugs is effective 
for some patients, but many LGS patients continue to have 
  seizures even with the use of multiple antiepileptic drugs, 
and combination therapy puts these patients at increased 
risk for experiencing side effects.1,7,8 It is clear that new 
options are necessary for these treatment-resistant patients. 
One such option is the use of clobazam, a 1,5-benzodi-
azepine, which may be particularly effective in pediatric 
populations.
Clobazam, a 1,5-benzodiazepine
Clobazam was initially proposed as an effective anticon-
vulsant and anxiolytic with an improved side effect profile 
compared with the 1,4-benzodiazepines, which include diaz-
epam and clonazepam (Figure 1).2,40,41 The original report42 
found clobazam to be effective in several animal models of 
acute seizures, and it was first reported to have therapeutic 
activity in patients with a variety of seizure disorders by 
Gastaut and Low in 1979.43 Clobazam (marketed under the 
brand names Frisium®, Urbanyl®, Onfi, and Mystan®) is now 
available in many countries as adjunctive therapy for several 
types of seizures.
Clobazam acts primarily through positive allosteric 
modulation of GABAA receptors, a mechanism of action 
shared by all clinically useful benzodiazepines. These ligand-
gated chloride channels are responsible for fast inhibitory 
neurotransmission throughout the central nervous system, 
and drugs that enhance their activity are often effective 
anxiolytics, sedatives, and anticonvulsants. While the ben-
zodiazepines are widely considered to be safe and effective 
for the treatment of acute seizures, their clinical utility for 
long-term therapy is often limited by side effects and the 
development of tolerance.41
Metabolism of clobazam
The primary pathway for metabolism of clobazam is dem-
ethylation by cytochrome P450 (CYP)3A4 and CYP2C19 
to its active metabolite n-desmethylclobazam (norclobazam, 
  Figure 1).44 Clobazam can be hydroxylated to an inactive form, 
but this appears to be a minor pathway. CPY2C19 also acts 
on norclobazam, inactivating it through hydroxylation.44,45 
Since norclobazam itself is an anticonvulsant, an increase in 
its levels through inhibition of CYP2C19 can greatly increase 
the duration of therapeutic effect. Mutations in CYP2C19 that 
reduce its activity are relatively common, with nearly 3% of 
Caucasians and up to 20% of Asians characterized as “poor 
metabolizers”.46 In epileptic patients treated with clobazam, the 
norclobazam to clobazam ratio was found to be dramatically 
higher in those with mutations in CYP2C19.44,47,48 Interestingly, 
one study found that clobazam therapy was more effective in 
patients with defective CYP2C19 alleles, with no correlation to 
adverse side effects,49 which may suggest a prominent role for 
norclobazam in determining the therapeutic benefits. However, 
others have reported an increased occurrence of side effects, 
primarily sedation, with clobazam administration in patients 
carrying CYP2C19 mutations, and clobazam doses may need 
to be reduced for some in this patient population.47
Studies in animal models of seizure 
and epilepsy
Clobazam has demonstrated effectiveness in a wide variety 
of animal models, including acute and chronic seizures and 
genetic forms of epilepsy.2,50 In recent studies,   clobazam 
generally showed efficacy similar to that of the 1,4-
  benzodiazepines, albeit with lower potency when compared 
with diazepam or clonazepam.51–54 The side effect profile, 
development of tolerance, and withdrawal hyperexcitability 
produced by clobazam were all similar to that seen with 
diazepam in these animal models.51 However, the activity 
of clobazam was not identical to the 1,4-benzodiazepines in 
all cases, because clobazam was found to be more effective 
in a model of inherited epilepsy,53 and had a distinct profile 
of activity against acute seizures.51
Activity at GABAA receptors
A variety of studies have clearly shown that, like the 1,4-
benzodiazepines, clobazam is a positive allosteric modulator 
of GABAA receptors. Direct enhancement of the response by 
clobazam to applied GABA was demonstrated in cultured 
cortical55 and cerebellar56 neurons, and clobazam was also 
found to slow the decay of miniature inhibitory post-synaptic 
currents in brain slices from rat hippocampus.57
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Figure  1  Clobazam  (7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione). 
Structures of diazepam, clobazam, and norclobazam and major metabolic pathways 
for clobazam and norclobazam.  
Note: Clobazam is primarily metabolized by demethylation to n-desmethylclobazam 
(norclobazam). Dashed line indicates a minor pathway by hydroxylation. Norclobazam 
is hydroxylated to an inactive compound mainly through the activity of CYP2C19. 
Adapted with permission from Giraud C, Tran A, Rey E, vincent J, Tréluyer JM, Pons G.   
in vitro characterization of clobazam metabolism by recombinant cytochrome P450 
enzymes: importance of CYP2C19. Drug Metab Dispos. 2004;32:1279–1286.44
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Neuronal GABAA receptors are structurally   heterogeneous, 
and the pentameric channel can be assembled from a 
  combination of at least 16 different subunit subtypes (includ-
ing α1–6, β1–3, γ1–3, δ, ε, π, and θ).58 These subunits show 
different patterns of expression throughout the brain, and 
their levels change throughout development and in response 
to pathological conditions, including seizure activity.59 The 
subunit composition of the receptor greatly influences its 
pharmacological properties.
Benzodiazepine agonists do not modulate receptors 
containing α4 or α6 subunits, and require the presence of a 
γ subunit.60 Clobazam appears to share the same binding site 
as other benzodiazepine agonists, because a mutation in the 
γ subunit had a similar effect on potency of both diazepam 
and clobazam.61 However, clobazam and norclobazam have 
been tested directly on very few GABAA receptor isoforms, 
and no comprehensive studies of the subunit dependence of 
their activity have been reported for either compound.
The modulatory activity of clobazam, norclobazam, and 
diazepam was compared at recombinant α3β3γ2 receptors,62 
which is likely to be a significant isoform in the developing 
brain.59 In that study, clobazam had efficacy similar to that 
of diazepam, but lower potency, consistent with the higher 
clobazam doses required in animal studies. Relative to one 
another, norclobazam and clobazam had similar potency 
at these receptors, although norclobazam showed lower 
  efficacy.62 Few other studies have been performed to examine 
the possible subunit dependence of clobazam or norcloba-
zam activity at GABAA receptors. Clobazam was shown 
to enhance the response of α1β2γ1 receptors modestly63 
and to bind to an α5-containing receptor population from 
rat hippocampus with characteristics similar to those of 
  diazepam.64 It is important to understand whether clobazam 
or norclobazam show a different pattern of subunit selec-
tivity compared with other benzodiazepines, which might 
explain the distinct characteristics associated with clobazam. 
Drugs that modulate different receptor populations would be 
expected to have unique effects on seizure activity, sedation, 
and anxiety,65,66 and could also produce different levels of 
tolerance development and abuse potential.67
In addition to direct modulation of GABAA receptor activ-
ity, clobazam was shown to cause a region-specific increase 
in expression of transporters for GABA (GAT3) and gluta-
mate (GLT-1) in an animal model of temporal lobe   epilepsy.68 
This alteration may have been an indirect effect from the 
reduction in seizure activity, because clobazam had no 
effect on transporter levels in control   (seizure-free)   animals. 
The impact of these changes in the clinical   effectiveness 
of clobazam is not known, but an increase in GLT-1 could 
potentially reduce the high hippocampal glutamate levels 
associated with epileptogenesis in animal models of tem-
poral lobe epilepsy.69 Modulation of voltage-gated Na+ and 
Ca2+ channels by clobazam has also been suggested by some 
authors,2,70 although no studies have demonstrated a direct 
action at these channels.
Does norclobazam have a 
therapeutic role?
It is clear that norclobazam is an active metabolite of cloba-
zam, with direct anticonvulsant activity both in animal mod-
els of epilepsy and in patients with refractory epilepsy.70 Less 
clear are the relative roles of each of these compounds in the 
therapeutic and side effect profiles of clobazam. In epilepsy 
patients, the degree of seizure control was correlated with 
blood levels of norclobazam rather than clobazam.72   Studies 
with both neurons and recombinant expression systems 
have shown that norclobazam acts as a positive allosteric 
modulator of GABAA receptors, with a similar potency but 
lower efficacy than clobazam.55,62 It has been suggested that 
partial agonists at modulatory sites might have improved 
side effect profiles compared with full agonists,73 and indeed, 
norclobazam was associated with reduced development 
of tolerance compared with clobazam in a mouse seizure 
model.71 However, very few studies have directly examined 
the properties of norclobazam. If norclobazam is a primary 
mediator of the anticonvulsant effects of clobazam, further 
studies into its mechanism(s) of action are warranted.
Clinical trials in Lennox–Gastaut 
syndrome and other pediatric 
epilepsies
Clobazam was first synthesized in the 1960s and is approved 
for use as an antiepileptic drug in over 100 countries.2 Thus, 
longstanding clinical experience indicates that clobazam 
is a safe and effective addon therapy for many patients 
(Table 1). In many countries, clobazam has been used as 
a first-line antiepileptic drug in pediatric epilepsy, and in 
spite of other options becoming available, it continues to be 
used as an adjunctive therapy for patients with treatment-
resistant epilepsy.74–76 In the US, until its October 2011 
approval by the Food and Drug Administration, clobazam 
was only obtained from foreign pharmacies and paid for 
out-of-pocket by patients. Thus, the use of clobazam in the 
US was typically limited to patients with severe epilepsy that 
had proven   refractory to multiple medication options.30,77 
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Table 1 Clobazam as addon therapy in refractory pediatric epilepsy
Study Trial design Participants and  
included diagnoses
Dosage Results
Conry et al8 Phase ii, multicenter,  
randomized,  
double-blind,  
dose-ranging
68 patients  
(42 males, 26 females) 
2–26 years 
LGS
0.25 mg/kg/day  
or 1.0 mg/kg/day
0.25 mg/kg/day: 38% of patients had  
a $50% decrease in drop seizure frequency 
1.0 mg/kg/day: 83% of patients had  
a $50% decrease in drop seizure frequency
Conry et al87 Phase iii, multicenter,  
randomized,  
double-blind,  
dose-ranging,  
placebo-controlled
238 patients 
2–54 years 
LGS
0.25 mg/kg/day, 
0.5 mg/kg/day,  
or 1.0 mg/kg/day
0.5 mg/kg/day: 58% of patients had  
a $50% decrease in drop seizure frequency 
1.0 mg/kg/day: 77% of patients had  
a $50% decrease in drop seizure frequency
da Silveira  
et al84
Retrospective 100 patients  
(61 males, 39 females) 
1–18 years 
Refractory focal epilepsy
5–60 mg/day 33% of patients had a $75% decrease  
in seizure frequency
Farrell78 Open-label,  
prospective
50 patients, 33 with LGS2,  
16 years 
Refractory epilepsy
5–40 mg/day 54% of patients had a $50% decrease  
in seizure frequency
Jan and  
Shaabat79
Open-label,  
prospective
31 patients  
(21 males, 10 females),  
14 with LGS 
2 months to 15 years 
intractable childhood epilepsy
5–40 mg/day 80% of patients had a $50% decrease  
in seizure frequency
Kalra et al81 Open-label,  
prospective
88 patients  
(59 males, 29 females) 
7 months to 12 years 
refractory epilepsy
0.3–2.0 mg/kg/day 85% of patients had a $50% decrease  
in seizure frequency
Keene et al86 Double-blind,  
placebo-controlled, 
crossover
21 patients  
(11 males, 10 females) 
2–19 years 
Refractory epilepsy
0.25–1.0 mg/kg/day 54% of patients had a $50% decrease  
in seizure frequency
Munn and  
Farell74
Open-label,  
prospective
115 patients  
(68 males, 47 females),  
25 with LGS 15 months to 17 years 
refractory epilepsy
0.36–3.8 mg/kg/day 62% of all patients had a $50% decrease  
in seizure frequency 
64% of LGS patients had a $50% decrease  
in seizure frequency
Silva et al85 Retrospective 97 patients (58 males,  
39 females),  
26 with LGS, 2 with LGS and  
west syndrome 
1–17 years 
Epileptic encephalopathy
5–60 mg/day 37% of patients had a $50% decrease  
in seizure frequency
Sheth et al82 Open-label,  
prospective
63 patients  
(30 males, 33 females),  
14 with LGS 
3–20 years 
intractable epilepsy
Average  
0.8 mg/kg/day
65% of patients had $50% decrease  
in seizure frequency
Sugai80 Open-label,  
prospective
Short term: 55 patients, 8 with LGS 
Long-term: 31 patients, 4 with LGS 
Refractory epilepsy
0.28–1.25 mg/kg/day Short term: 71% of all patients and 62%  
of LGS patients had a $50% decrease  
in seizure frequency 
Long-term: 81% of all patients and 50%  
of LGS patients had a $50% decrease  
in seizure frequency
vadja et al83 Open-label,  
prospective or  
double-blind,  
placebo-controlled,  
crossover
14 patients*  
(5 males, 9 females),  
7 with LGS 
6–38 years 
Refractory epilepsy
15–60 mg/day 40% of patients had a $50% decrease  
in seizure frequency
Note: *Results not reported for four patients.
Abbreviation: LGS, Lennox–Gastaut syndrome.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
677
Adjunctive clobazam in Lennox–Gastaut syndromeNeuropsychiatric Disease and Treatment 2011:7
However, clobazam is anticipated to be more widely available 
from early 2012 for LGS patients. Clobazam was granted 
orphan drug status by the Food and Drug Administration in 
December 2008, and a new drug application submitted in 
March 2011 for use in children with LGS was approved in 
October 2011.
In six open-label prospective studies evaluating the effi-
cacy of clobazam as addon therapy for pediatric patients with 
refractory epilepsy, 54%–85% of patients experienced at least 
a 50% decrease in seizure frequency74,78–83 (Table 1). These 
studies included a total of 423 patients, with 98 patients iden-
tified as having LGS. Most studies did not provide distinct 
data for the LGS population, but Sugai80 reported that 62% of 
LGS patients in the group evaluated for short-term efficacy 
and half of LGS patients followed for at least 6 months had 
a 50% or greater decrease in seizure frequency on clobazam. 
In another study, 64% of 25 patients with LGS achieved at 
least a 50% decrease in seizure frequency.74 Jan and Shaabat79 
noted that three of the 14 LGS patients included in their study 
continued to have daily seizures while taking clobazam, 
a higher proportion than in the rest of the study population.
Two retrospective studies on the efficacy of clobazam as 
addon therapy for pediatric patients also reported significant 
reductions in seizure frequency84,85 (Table 1). Da Silveira 
et al84 evaluated 100 patients who received clobazam as 
addon therapy for refractory focal epilepsy, and 33% of   
these patients had a 75% or greater decrease in seizure 
frequency. Silva et al85 reviewed the efficacy of clobazam 
as addon therapy for 97 pediatric patients with epileptic 
encephalopathies. Of the patients in this study, 28 had LGS. 
Thirty-seven percent of all patients had a 50% or greater 
decrease in seizure frequency, and complete seizure control 
was achieved in nine patients.
In 1990, Keene et al86 reported the results of a double-blind, 
placebo-controlled, crossover study evaluating clobazam as 
addon therapy in 21 patients aged 2–19 years with refractory 
epilepsy. Fifty-two percent of patients in the clobazam arms had 
a 50% or greater decrease in seizure frequency. More recently, 
Conry et al8 reported the results of a multicenter,   double-blind 
Phase II study evaluating low-dose (0.25 mg/kg/day) or 
high-dose (1 mg/kg/day) clobazam in 68 patients with LGS, 
aged 2–26 years. Eighty-three percent of patients in the 
high-dose group had a 50% or greater reduction in seizure 
frequency compared with baseline. In addition to decreased 
seizure frequency, patients had improved global assessments 
on both high-dose and low-dose clobazam,8 consistent with 
prior work suggesting improved cognitive and behavioral 
performance on clobazam.74,78 Following the encouraging 
results of the Phase II study, a multicenter,   randomized, 
double-blind, Phase III study was performed.87 This study 
evaluated the efficacy of low-dose (0.25 mg/kg/day), medium-
dose (0.5 mg/kg/day), and high-dose (1 mg/kg/day) clobazam 
versus placebo as addon therapy for 238 patients with LGS, 
aged 2–54 years. Fifty-eight percent of patients in the medium-
dose group and 77% of patients in the high-dose group had a 
50% or greater decrease in seizure frequency. Improved global 
assessments were reported for patients in all dosage groups 
compared with placebo.
Adverse effects in epilepsy patients
Adverse effects from clobazam are generally similar to those 
of the other benzodiazepines, but perhaps less frequent. 
Conry et al8 reported little difference in the occurrence of side 
effects in patients receiving clobazam 0.25 mg/kg/day and 
those receiving 1.0 mg/kg/day. The most common adverse 
effect is somnolence, reported by 9%–19% of patients.8,78,81,84 
Other common side effects include behavioral abnormalities, 
irritability, ataxia, and drooling, each occurring in under 10% 
of patients.8,81,84 Notably, in spite of the efficacy observed in 
many patients, an increase in seizures, worsening of seizures, 
or development of new seizure types have been reported in 
up to 5%–13% of patients.8,74,80,84 In the only double-blind 
trial, Conry et al8 reported 13% with adverse events related to 
seizures, each mild or moderate in severity, and more common 
in the low-dose clobazam group than in the high-dose group. 
Other studies reporting adverse seizure-related events were 
open-label, prospective,74,80 or retrospective84 in nature without 
randomization or control arms. Because the rate and types of 
seizures often fluctuate over several weeks or months in patients 
with LGS, it remains unclear whether these episodes of seizure 
worsening are related to clobazam administration.3,8
Tolerance is an issue with many antiepileptic drugs, espe-
cially benzodiazepines, and the loss of efficacy of clobazam 
in some patients has been noted. Reports of the development 
of tolerance among published studies varied from as few as 
10% to as many as 87% of patients.81,84 For up to 70% of 
patients who developed tolerance, efficacy returned after 
stopping and reintroducing clobazam after 2–3 months or 
after increasing the dosage.74,80,81 Others noted persistent 
efficacy for more than one year in as many as 85% of patients 
who experienced improved seizure control, and some patients 
maintained complete seizure control during this time.85
Clobazam is typically initiated at a low dose, often 5 mg/
day or 0.1 mg/kg/day for smaller patients, and increased at 
5–7 day intervals until a minimum effective dose is reached 
or side effects occur.74,79 Studies have suggested that slow 
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titration may help avoid adverse effects and that when 
  present, side effects may be reduced or eliminated with 
dose reduction.79,80 Doses of 0.2–3.8 mg/kg/day2,73 have been 
used in trials evaluating the use of clobazam (Table 1). In 
our experience, doses up to 2 mg/kg/day divided into twice 
daily doses are often required. Rarely, higher doses up to 
3 mg/kg/day are required and tolerated.
Interactions with stiripentol and 
other antiepileptic drugs
Clobazam has been coadministered with a wide variety of 
other antiepileptic drugs, with few reported harmful drug–
drug interactions. Any inhibitors or inducers of CYP2C19 
can have an impact on clobazam and norclobazam levels, 
and coadministration of CYP2C19 inhibitors has been 
successfully used to enhance the duration and efficacy 
of clobazam treatment, possibly by increasing levels of 
norclobazam. This interaction seems particularly ben-
eficial when clobazam is coadministered with stiripentol 
(Diacomit®), an antiepileptic drug, which is both a GABAA 
receptor modulator and a potent CYP2C19 inhibitor.88–90 
Clobazam and stiripentol act via separate mechanisms at 
the GABAA receptor57,62 and stiripentol can dramatically 
increase norclobazam levels.45 Animal studies have demon-
strated a significant positive interaction between clobazam 
and stiripentol, with both an additive pharmacodynamic 
interaction and a large increase in the brain concentration of 
clobazam.54 The combination of clobazam with stiripentol 
is widely used in the treatment of patients with Dravet syn-
drome (severe myoclonic epilepsy of infancy).88 In contrast 
with its possibly beneficial interaction with stiripentol, 
clobazam has also been reported to inhibit the metabolism 
of valproate, so has the potential to increase valproate-
associated toxicity.91 Overall, clobazam is generally well 
tolerated when combined with most of the antiepileptic 
drugs commonly used in clinical practice.
Summary
LGS is an epileptic encephalopathy with childhood onset 
that is characterized by multiple seizure types and an 
intractable nature. LGS is also associated with a num-
ber of cognitive and behavioral problems that progress 
over time, often even after seizure control has improved. 
Clobazam has been demonstrated to decrease the overall 
rate of seizures in patients with LGS, with a significant 
reduction in the frequency of drop seizures, often consid-
ered to be the most disabling type of seizure associated 
with the syndrome.3,6,10,12 Improved global   assessments for 
patients on clobazam have been noted, which may warrant 
further investigation. Hancock and Cross7 reported that the 
behavioral and cognitive deterioration associated with LGS 
are the symptoms that are hardest to cope with for many 
families. Further work needs to be done to characterize 
fully the activity of both clobazam and norclobazam, its 
active metabolite, at different GABAA receptor popula-
tions and to optimize the incorporation of clobazam into 
a treatment plan.
Clobazam has been used as a first-line treatment in 
many countries, and is now frequently used as an adjunc-
tive therapy for patients with refractory epilepsy. Its recent 
approval by the Food and Drug Administration will now 
allow its use for LGS patients in the US. The antiepileptic 
drugs currently approved for the treatment of LGS are 
not effective for all patients and each is associated with 
significant side effects. Other safe and effective options for 
treatment-resistant patients are needed, and recent studies 
of clobazam suggest that it may be an effective and well 
tolerated option for patients with LGS.
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